Top segments and regional performance

Last year, the company generated ‪173.82 M‬ AUD, the most of which — ‪177.46 M‬ AUD — came from its top-performing segment, Allogeneic Cellular Medicines Platform, compared to ‪26.56 M‬ AUD the previous year. The greatest contribution came from Australia, United States, Singapore, United Kingdom and Switzerland, which accounted for ‪177.46 M‬ AUD last year, with ‪26.56 M‬ AUD the year before.